{
    "clinical_study": {
        "@rank": "129327", 
        "arm_group": [
            {
                "arm_group_label": "Depo-Provera", 
                "description": "Women who choose to initiate Depo-Provera"
            }, 
            {
                "arm_group_label": "Mirena", 
                "description": "Women who choose to initiate Mirena (intrauterine device)"
            }, 
            {
                "arm_group_label": "Oral contraception", 
                "description": "Women who choose to initiate oral contraception"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators are conducting a research study to understand how cells responsible for\n      fighting infection (immune cells) are affected by hormonal contraceptive use.  The\n      investigators hypothesize that progestin-containing hormonal contraceptives (i.e.,\n      Depo-Provera) inhibit host response to infection.  To test this hypothesis, the\n      investigators will collect blood and genital tract samples from women before and after their\n      initiation of a hormonal contraceptive (either birth control pills, Depo-Provera, or\n      Mirena)."
        }, 
        "brief_title": "Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Initiation of Oral Contraception (OC)", 
            "Initiation of Depo-Provera (DMPA)", 
            "Initiation of Mirena (LNG-IUD)"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 15-25 years of age (inclusive)\n\n          2. History of regular menstrual cycle\n\n          3. Not pregnant\n\n          4. No plan to become pregnant in the next 3 months\n\n          5. Interested in beginning use of OC, DMPA, or LNG-IUD\n\n          6. Able to read and provide written informed consent (and consent from a parent/guardian\n             if the participant is a minor)\n\n        Exclusion Criteria:\n\n          1. Anticipated move out of area that prevents return for a follow-up visit\n\n          2. Unavailability for follow-up visit\n\n          3. Less than 90 days post-partum or post-abortion\n\n          4. Sexually transmitted infection (STI) diagnosed less than 30 days prior to enrollment\n\n          5. Use of OC, contraceptive ring or patch, single rod implant, LNG-IUD, or\n             copper-containing IUD less than 3 months prior to enrollment\n\n          6. DMPA injection less than 6 months prior to enrollment\n\n          7. History of immunosuppressive condition of current use of immunosuppressive\n             medications\n\n          8. History of a cervical malignancy\n\n          9. Detection of cervical anatomic pathologic conditions that preclude cervical biopsy\n             procurement\n\n         10. Intolerance or contradiction to use of OC, DMPA, or LNG-IUD"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "25 Years", 
            "minimum_age": "15 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Women interested in initiating hormonal contraceptive use"
            }
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750476", 
            "org_study_id": "PRO12010187", 
            "secondary_id": "R01HD072663"
        }, 
        "intervention": [
            {
                "arm_group_label": "Mirena", 
                "intervention_name": "Mirena", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Oral contraception", 
                "intervention_name": "Oral contraception", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Depo-Provera", 
                "intervention_name": "Depo-Provera", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Levonorgestrel", 
                "Medroxyprogesterone", 
                "Medroxyprogesterone Acetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "oral contraception", 
            "Depo-Provera", 
            "Mirena"
        ], 
        "lastchanged_date": "January 5, 2014", 
        "link": {
            "description": "Cherpes Research Group", 
            "url": "http://www.chp.edu/CHP/cherpeslab"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15213"
                }, 
                "name": "UPMC Adolescent Clinic of Oakland"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives", 
        "overall_official": {
            "affiliation": "assistant professor", 
            "last_name": "Thomas L. Cherpes, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Proliferative capacity (i.e., ability to respond to antigen stimulation) of T cells isolated from the cervix of women before and after initiating a hormonal contraceptive", 
            "safety_issue": "No", 
            "time_frame": "Prior to and ~ 1 month (but up to 2 months) after initiation of a hormonal contraceptive"
        }, 
        "reference": [
            {
                "PMID": "22942424", 
                "citation": "Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, Terry-Allison T, St Leger AJ, Thomson AW, Cherpes TL. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J Immunol. 2012 Oct 1;189(7):3449-61. Epub 2012 Aug 31."
            }, 
            {
                "PMID": "22850275", 
                "citation": "Vicetti Miguel RD, Maryak SA, Cherpes TL. Brefeldin A, but not monensin, enables flow cytometric detection of interleukin-4 within peripheral T cells responding to ex vivo stimulation with Chlamydia trachomatis. J Immunol Methods. 2012 Oct 31;384(1-2):191-5. doi: 10.1016/j.jim.2012.07.018. Epub 2012 Jul 29."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750476"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Ohio State University", 
            "investigator_full_name": "Thomas Cherpes, DVM, MD", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Ohio State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Thomas Cherpes, DVM, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014", 
        "why_stopped": "PI and lab have re-located study to The Ohio State University"
    }
}